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COMMENTARY
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INTRODUCTION
Given the increasing complexity of the biomedical innova-
tion pipeline, collaboration across organizational, sectoral
and national boundaries is an increasingly important means
of leveraging resources and mitigating risk. The need to
jointly tackle systemic bottlenecks is particularly acute. Using
examples from EATRIS European infrastructure for transla-
tional medicine, we advocate for actors in all domains related
to preclinical translational research to expand their collab-
orative horizons to tackle the long-term systemic risks that
hamper drug development.
GOOD NEWS, BAD NEWS
From the perspective of biomedical innovation we are clearly
in exciting times, with the horizons of therapeutic feasi-
bility expanding into truly wondrous territory, albeit in fits
and starts. Driven in part by ever more sensitive analytical
technologies increasing our mechanistic understanding of
underlying pathologies, we’re shifting from populations to the
n = 1 indication1, from a phenotypical description of dis-
ease to a molecularly-based taxonomy2, and all the while the
number of new therapeutic strategies increases steadily. It is
heartening to witness these - and many other - mini revolu-
tions in the making.
On the other hand, in the shadow of 2016’s disap-
pointing and abrupt end to the recent uptick in new drug
authorizations,3 cause for optimism is somewhat blunted.
Moreover with the late stage clinical failure rates remain-
ing stubbornly high4, pipeline productivity is clearly sorely in
need of efficiency gains.
The development pathway remains littered with systemic
bottlenecks acting as a drag on the process. As increas-
ingly complex products enter the pipeline, with each novel
strategy bringing with it technical and regulatory uncertain-
ties, many bottlenecks will stagnate into systemic risks that
affect all similar projects in the pipeline. In the highly frag-
mented biomedical research eco-system, these systemic
bottlenecks are often addressed with project-specific solu-
tions that may never be shared or are not applicable to the
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wider risk. This leaves a patchwork approach to innovation
that does little to improve system-wide efficiency, and can
lead to undesired duplication of efforts. Furthermore, as neg-
ative results are rarely published, we will never know the
full extent to which resources are being thrown at dead-end
tracks by multiple parties at the same time. This tragedy
of the biomedical commons must be tackled with greater
urgency and combined firepower if we are to have any hope
of reducing the cost and duration of drug development.
COMPLEX NETWORK, VALUABLE OUTCOMES
In Europe and abroad we are witnessing a growing number
of initiatives, both public-private and public-public, that seek
to address the systemic deficiencies dogging the pipeline,
which is a welcome development. Not only the quantity,
but the scope and breadth of these collaborations seem
to be expanding, implying that the cost and complexity of
highly networked, multi-sectoral collaboration is dropping
such that the benefits outweigh the risks. A good example
is the Innovative Medicines Initiative (IMI), involving Europe’s
pharma partners in EFPIA, the European Commission and
Europe’s academia, as well as regulators and patients. The
second cycle, started in 2014, has a combined budget of
over €3.2 billion and aims to build on the success of the first
round.5
Europe’s regulators, too, have in recent years become
much more open and collaborative in their stance, while nat-
urally remaining cautious to prevent conflicts of interest. In
acknowledgment of the increasing complexity of medicinal
products and the need for evidence-based regulatory trans-
parency to stimulate innovation, the European Medicines
Agency’s recently published framework for engagement with
academia includes an objective “to ensure that the best sci-
entific expertise and academic research are available to sup-
port timely and effective evidence generation”.6 This would
entail a tripartite initiative requiring regulators, independent
research labs and non-commercial funders working in uni-
son to answer emerging regulatory science questions - a very
exciting development, particularly for the advanced therapy
field.
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At EATRIS ERIC, the European Infrastructure for Transla-
tional Medicine, working on pipeline productivity is a critical
part of their strategy. Important activities to this end seek
solutions to some of those aforementioned systemic bot-
tlenecks, such as identifying and validating tools to better
predict the likelihood of proof of concept, reduction of vari-
ability through harmonization and standardization exercises,
and validation of biology to support precision medicine. A
key initiative for EATRIS involves collaborators from around
the globe, including Therapeutic Innovation Australia, the
Center for Drug Research and Development (CDRD) in
Canada, LifeArc (formerly MRC Technology) in the UK, and
NIH’s National Center for Advancing Translational Sciences
(NCATS). The logistical challenges of such a geographically
spread initiative, including holding monthly teleconferences
spanning 14 time-zones, have been far outweighed by the
advantages of bringing together likeminded experts in the
field7. Structured as a modular, light collaboration, the group
identifies joint advocacy, educational, technical and harmo-
nization projects in a bottom-up manner, with operational
teams formed on a voluntary basis.
One of their recently launched projects serves as an excel-
lent example of the simple, yet vitally important exercises
that such collaborations permit. A high-throughput screen-
ing (HTS) system ring-testing project being piloted by NIH
NCATS and EATRIS member institute IMTM in Olomouc,
Czech Republic, is under development in order to identify
drivers of variability in HTS, as well as to provide feedback
to HTS sites on potential sources of variability in their sys-
tems. Once piloted successfully, the initiative will be opened
to wider collaboration (see “EATRIS Inside” in Supplemen-
tary Information).
Within the cancer therapeutics field, the alarming rate of
failure among clinical trials is a major issue that partly results
from the use of inadequately predictive 2D in vitro tumor
models for the screening of promising hits and leads in pre-
clinical studies. Within EATRIS, several institutes focus on the
utilization of novel 3D in vitro tumor models that reproduce
in vivo tumor complexities for effective drug selection in the
preclinical stages of drug development.
In addition to the lamentable lack of standards in the field, a
further major challenge facing translational scientists is a lim-
ited understanding of how disease in preclinical animal mod-
els translates to humans, which likely further contributes to
the high attrition rate in phase II and III clinical trials8. Strate-
gies to overcome this include not only development and
validation of novel models with higher predictivity, but also
efforts to overcome the current limitations in the experimen-
tal design and statistical analysis of studies utilizing current
in vivo models9. In a collaboration of several Finnish mem-
ber institutes of EATRIS, a computational algorithm has been
made freely available that matches the animals based on all
available baseline variables, and thus assists researchers in
optimizing the study design and minimizing the number of
animals needed to achieve statistically significant results (see
Supplementary Information). This provides the researcher
with a variety of options to conduct adequately powered and
fully-randomized preclinical intervention studies.
Another EATRIS program that can impact systemic inef-
ficiency is underway in collaboration with the European
Association of Nuclear Medicine (EANM), to enable multi-
center clinical trials utilizing PET imaging tracers using
zirconium-89 (89Zr), that finds increasing application in so-
called “immuno-PET” studies of biologicals, nanomedicines,
and cells. The 89Zr-PET/CT accreditation programme will
facilitate cross-calibration of PET/CT imaging devices and
image reconstruction in a standardized manner, allowing
data to be shared and pooled with sufficient quantitative
accuracy.
System-wide improvements need not be limited to the
technical bottlenecks affecting drug developers and research
labs. There are a myriad of operational bottlenecks that
plague the translational research system, such as efficient
access to high-quality biological samples with associated
clinical data, access to pre-competitive funding for the vali-
dation of promising tools such as imaging tracers, and reli-
ability of the peer review system for selection of applied
research projects. With regards to the latter EATRIS has been
working with public and non-profit private funders for sev-
eral years, collaborating with them to support their trans-
lational research portfolios, in the recognition that these
entities are not uniformly aware of the differing require-
ments of funding and executing confirmatory research vs.
exploratory research (see “EATRIS Inside” in Supplementary
Information).10
NOT ALL PLAIN SAILING
Developing and running initiatives involving multiple orga-
nizations, regions, and sectors brings with it the complexi-
ties and inefficiencies inherent to networked activities, with
the added unknowns of foreign (organizational) cultures and
mores waiting to entrap the uninitiated. It is thus important
that the potential profit to be had from collaborating out-
weighs the additional burden. Regarding the former - in the
case of multi-party collaborations - an important operational
concept is that of modularity, whereby not all partners in the
initiative are forced into each sub-project. This ensures that
all partners can be satisfied contributing to activities that are
important to them, choosing to pass on projects that are
not aligned with their own priorities. Additionally, it is always
wise to build in mechanisms whereby free-riders and non-
performers can be censured and eventually ejected.
Sadly, not all collaborations deliver on their initial promise
despite the good intentions of those involved. Common
showstoppers include low organizational priority of “unsexy
pre-competitive projects,” cultural inertia preventing leading
edge developments from taking hold, and unbalanced contri-
butions or prioritization from partners leading to chagrin and
eventual abandonment. In all of the above the adequate vet-
ting of partners, gradual build-up of joint activities, and strong
management of the initiative can go a long way to minimizing
these risks.
KEEP GOING GLOBAL
Given the increasing complexity of the biomedical innova-
tion pipeline, collaboration across boundaries is an increas-
ingly important means of leveraging resources and mitigat-
ing risk. Joint ventures have long been a bulwark of product
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development in the truly global drug market; we believe that
extending these types of relationships to the pre- and non-
competitive space is logical, as long as the risks and inef-
ficiencies associated with doing so are outweighed by the
benefits. Our experience thus far certainly indicates so.
The benefits are clear - increasing quality in an age where
the reproducibility of foundational research is under intense
scrutiny, reducing variability in a pipeline with poor predic-
tivity of clinical success, and validating (biological) tools to
increase confidence and reduce cycle time are all worthy out-
comes. The huge number of bottlenecks, combined with the
need for consensus when talking of standards and harmo-
nization, leaves few alternatives to boundary spanning. By
working together on the issues that bind us to a poorly per-
forming pipeline, we can transform the tragic patchwork of
competition into a more efficient innovation continuum. By
better sharing the costs and risks of developing the tools
that help us make better drugs, we can improve the cost-
effectiveness of R&D without sacrificing competitiveness,
thereby delivering more value to patients and payors.
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